Nature, the master of craftsman of molecules created almost an inexhaustible array of molecular entities. It stands as an infinite resource for drug development, novel chemotypes and pharmacophores, and scaffolds for amplification into efficacious drugs for a multitude of disease indications and other valuable bioactive agents. Plants have been the basis of many traditional medicine systems throughout the world for thousands of years and continue to provide mankind with new remedies. The use of plants as medicines has a long history in the treatment of various diseases. The plant-derived compounds have a long history of clinical use, better patient tolerance and acceptance. To date, 35,000-70,000 plant species have been screened for their medicinal use. The first commercial pure natural product introduced for therapeutic use is morphine marketed by Merck in 1826, and the first semi-synthetic pure drug aspirin, based on a natural product salicin isolated from Salix alba, was introduced by Bayer in 1899. This led to the isolation of early drugs such as cocaine, codeine, digitoxin, quinine and pilocarpine, of which some are still in use and several other recent plant derived compounds, which have undergone development and have been marketed as drugs which include Paclitaxel from Taxus brevifolia for lung, ovarian and breast cancer, Artemisinin from traditional Chinese plant Artemisia annua to combat multidrug resistant malaria, Silymarin extracted from the seeds of Silybum marianum for the treatment of liver diseases.
The TargetMol’s Selected plant-sourced compound Library, a unique collection of 1825 plant-sourced compounds that derived from 277 plant species, can be used for natural drug screening and new drug development.
|100 μL * 10 mM (in DMSO)||22463.00|
|250 μL * 10 mM (in DMSO)||31547.00|